RESUMO
BACKGROUND: Financial toxicity, defined as both the objective financial burden and subjective financial distress from a cancer diagnosis and its treatment, is a topic of interest in the assessment of the quality of life of patients with cancer and their families. Current evidence implicates financial toxicity in psychosocial, economic and other harms, leading to suboptimal cancer outcomes along the entire trajectory of diagnosis, treatment, supportive care, survivorship and palliation. This paper presents the results of a virtual consensus, based on the evidence base to date, on the screening and management of financial toxicity in patients with and beyond cancer organized by the European Society for Medical Oncology (ESMO) in 2022. METHODS: A Delphi panel of 19 experts from 11 countries was convened taking into account multidisciplinarity, diversity in health system contexts and research relevance. The international panel of experts was divided into four working groups (WGs) to address questions relating to distinct thematic areas: patients with cancer at risk of financial toxicity; management of financial toxicity during the initial phase of treatment at the hospital/ambulatory settings; financial toxicity during the continuing phase and at end of life; and financial risk protection for survivors of cancer, and in cancer recurrence. After comprehensively reviewing the literature, statements were developed by the WGs and then presented to the entire panel for further discussion and amendment, and voting. RESULTS AND DISCUSSION: A total of 25 evidence-informed consensus statements were developed, which answer 13 questions on financial toxicity. They cover evidence summaries, practice recommendations/guiding statements and policy recommendations relevant across health systems. These consensus statements aim to provide a more comprehensive understanding of financial toxicity and guide clinicians globally in mitigating its impact, emphasizing the importance of further research, best practices and guidelines.
Assuntos
Neoplasias , Humanos , Neoplasias/terapia , Neoplasias/economia , Consenso , Qualidade de Vida , Efeitos Psicossociais da Doença , Oncologia/economia , Oncologia/normas , Sociedades Médicas , Técnica DelphiRESUMO
The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument to screen, assess and monitor malnutrition and risk factors, and to triage for interventions. After having translated and culturally adapted the original PG-SGA for the Italian setting, according to International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Principles, we tested linguistic validity, i.e., perceived comprehensibility and difficulty, and content validity (relevance) of the Italian version of the PG-SGA in patients with cancer and a multidisciplinary sample of healthcare professionals (HCPs). METHODS: After the translation and cultural adaptation of the original PG-SGA for the Italian setting, the patient component (i.e., PG-SGA Short Form (SF) was tested for linguistic validity (i.e., comprehensibility ad difficulty) in 120 Italian patients with cancer and 81 Italian HCPs. The full PG-SGA, i.e., patient and professional component of the PG-SGA, was tested for content validity, i.e., relevance, in 81 Italian HCPs. The data were collected by a questionnaire and evaluations were operationalized by a 4-point scale. Through item and scale indices we evaluated the comprehensibility (I-CI, S-CI), difficulty (I-DI, S-DI) and content validity (I-CVI, S-CVI). Scale indices 0.80-0.89 were considered acceptable, and scale indices ≥0.90 were considered excellent. RESULTS: Patients perceived comprehensibility and difficulty of the PG-SGA SF (Boxes) as excellent (S-CI = 0.98, S-DI = 0.96). Professionals perceived comprehensibility of the professional component (Worksheets) as excellent (S-CI = 0.92), difficulty as acceptable (S-DI = 0.85), and content validity of the full PG-SGA as excellent (S-CVI = 0.92). Dietitians gave higher scores (indicating better scores) on comprehensibility, difficulty, and content validity of Worksheet 4 (physical exam) than the other professions. In Worksheet 4, four items were considered most difficult to complete and were considered below acceptable range. Relevance was perceived as excellent by professionals for both the patient component (S-CVI = 0.93) and the professional component (S-CVI = 0.90), resulting in S-CVI = 0.92 for the full PG-SGA. Slight textual modifications were implemented resulting in the final version of the Italian PG-SGA. CONCLUSIONS: Translation and cultural adaptation of the original PG-SGA resulted in the Italian version of the PG-SGA that maintained its original purpose and meaning and can be completed adequately and easily by patients and professionals. The Italian PG-SGA is considered relevant for screening, assessing and monitoring malnutrition and risk factors, as well as triaging for interventions by Italian HCPs.
Assuntos
Desnutrição , Neoplasias , Humanos , Estado Nutricional , Avaliação Nutricional , Desnutrição/diagnóstico , Neoplasias/diagnóstico , Neoplasias/complicações , LinguísticaAssuntos
Neoplasias , Humanos , Prognóstico , Neoplasias/diagnóstico , Neoplasias/terapia , Cuidados Paliativos , PacientesRESUMO
Background: Co-infection rates increase in patients admitted to the Intensive Care Units. The aim of this study was to examine the Healthcare Associated Infections in critically ill adult patients infected with SARS-CoV-2. Methods: A retrospective observational study in adults with confirmed SARS-CoV-2 infection requiring intensive care unit admission was performed. From February 2020 to September 2021, healthcare records from a total of 118 patients were evaluated. Results: In the study period, 39 patients were diagnosed with at least 1 Healthcare Associated Infection (33.1%). The co-infection/co-colonisation rate >48 hours after admission was 29.0 per 1,000 person/days (95 % CI 19.1-33.9). A total of 94 isolates were identified, the most common being Klebsiella spp, Clostridium difficile, Acinetobacter baumanii and Enterococcus spp. Associated outcomes for Healthcare Associated Infections have been identified: age >64 years (p= .003), length of Intensive Care Unit stay> 7 days (p= .002), Type 2 Diabetes mellitus (p= .019), cardiovascular disease (p= .021), inserted central venous catheter (p= .014), intubation (p< .001), APACHE II score >25 (p< .001), mechanical ventilation 48 hours (p= .003), and inserted urinary catheter (p= .002). The overall fatality rate of patients included in the study was 41.5% (n= 49), and it was found to be significantly higher in patients who acquired a Healthcare Associated Infection (n=26/39, 66.7%) compared to those who did not acquire it (n= 23/79, 29.1%) (OR= 4.87; 95% CI = 2.14-11.10; p< .001). Conclusions: Our study showed high rates of Healthcare Associated Infections in critically ill adults with COVID-19. Associated factors for Healthcare Associated Infections acquisition and fatality in Intensive Care Units patients were identified as a good reason for a revision of existing infection control policies.
Assuntos
COVID-19 , Coinfecção , Infecção Hospitalar , Diabetes Mellitus Tipo 2 , Adulto , Humanos , Pessoa de Meia-Idade , COVID-19/epidemiologia , Estudos Retrospectivos , Estado Terminal , SARS-CoV-2 , Coinfecção/epidemiologia , Unidades de Terapia Intensiva , Infecção Hospitalar/epidemiologiaRESUMO
Macular degeneration is a leading cause of blindness. Treatments to rescue vision are currently limited. Here, we study how loss of central vision affects lateral feedback to spared areas of the human retina. We identify a cone-driven gain control mechanism that reduces visual function beyond the atrophic area in macular degeneration. This finding provides an insight into the negative effects of geographic atrophy on vision. Therefore, we develop a strategy to restore this feedback mechanism, through activation of laterally projecting cells. This results in improved vision in Cnga3-/- mice, which lack cone function, as well as a mouse model of geographic atrophy. Our work shows that a loss of lateral gain control contributes to the vision deficit in macular degeneration. Furthermore, in mouse models we show that lateral feedback can be harnessed to improve vision following retinal degeneration.
Assuntos
Atrofia Geográfica , Degeneração Macular , Degeneração Retiniana , Animais , Atrofia Geográfica/genética , Atrofia Geográfica/terapia , Degeneração Macular/genética , Camundongos , Células Fotorreceptoras Retinianas Cones/fisiologia , Degeneração Retiniana/complicações , Degeneração Retiniana/genética , Degeneração Retiniana/terapia , Visão OcularAssuntos
Neoplasias , Assistência Terminal , Adulto , Morte , Humanos , Neoplasias/epidemiologia , Neoplasias/terapia , Cuidados PaliativosAssuntos
Analgesia , Dor do Câncer , Administração Intravenosa , Adulto , Humanos , Morfina , Manejo da DorAssuntos
Constipação Intestinal/terapia , Impacção Fecal/terapia , Oncologia/normas , Neoplasias/complicações , Adulto , Fatores Etários , Idoso , Envelhecimento/fisiologia , Analgésicos Opioides/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Dor do Câncer/tratamento farmacológico , Dor do Câncer/etiologia , Constipação Intestinal/diagnóstico , Constipação Intestinal/etiologia , Constipação Intestinal/psicologia , Enema/efeitos adversos , Enema/métodos , Enema/normas , Europa (Continente) , Impacção Fecal/diagnóstico , Impacção Fecal/etiologia , Impacção Fecal/psicologia , Motilidade Gastrointestinal/efeitos dos fármacos , Motilidade Gastrointestinal/fisiologia , Humanos , Laxantes/administração & dosagem , Laxantes/efeitos adversos , Massagem/métodos , Massagem/normas , Oncologia/métodos , Neoplasias/sangue , Neoplasias/terapia , Autocuidado/métodos , Autocuidado/normas , Sociedades Médicas/normas , Supositórios/administração & dosagem , Supositórios/efeitos adversos , Resultado do TratamentoAssuntos
Delírio/terapia , Oncologia/normas , Neoplasias/complicações , Adulto , Idoso , Analgésicos Opioides/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Antipsicóticos/uso terapêutico , Dor do Câncer/tratamento farmacológico , Dor do Câncer/etiologia , Terapia Cognitivo-Comportamental/métodos , Terapia Cognitivo-Comportamental/normas , Delírio/diagnóstico , Delírio/epidemiologia , Delírio/etiologia , Desprescrições , Substituição de Medicamentos/métodos , Substituição de Medicamentos/normas , Europa (Continente) , Família , Humanos , Incidência , Institucionalização/estatística & dados numéricos , Programas de Rastreamento/métodos , Programas de Rastreamento/normas , Oncologia/métodos , Estadiamento de Neoplasias , Neoplasias/terapia , Educação de Pacientes como Assunto/métodos , Educação de Pacientes como Assunto/normas , Polimedicação , Fatores de Risco , Sociedades Médicas/normas , Assistência Terminal/métodos , Assistência Terminal/normasAssuntos
Dor do Câncer/terapia , Oncologia/normas , Neoplasias/complicações , Manejo da Dor/normas , Adulto , Analgésicos Opioides/normas , Analgésicos Opioides/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Dor Irruptiva/diagnóstico , Dor Irruptiva/epidemiologia , Dor Irruptiva/etiologia , Dor Irruptiva/terapia , Dor do Câncer/diagnóstico , Dor do Câncer/epidemiologia , Dor do Câncer/etiologia , Sobreviventes de Câncer , Europa (Continente) , Humanos , Oncologia/métodos , Estadiamento de Neoplasias , Neoplasias/diagnóstico , Neoplasias/patologia , Neoplasias/terapia , Manejo da Dor/métodos , Medição da Dor/métodos , Medição da Dor/normas , Dor Processual/diagnóstico , Dor Processual/epidemiologia , Dor Processual/etiologia , Dor Processual/terapia , Prevalência , Sociedades Médicas/normas , Assistência Terminal/métodos , Assistência Terminal/normas , Resultado do TratamentoAssuntos
Diarreia/terapia , Intolerância à Lactose/prevenção & controle , Oncologia/normas , Neoplasias/terapia , Cuidados Paliativos/normas , Adulto , Fatores Etários , Idoso , Analgésicos Opioides/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Biomarcadores/análise , Dor do Câncer/tratamento farmacológico , Dor do Câncer/etiologia , Diarreia/diagnóstico , Diarreia/etiologia , Diarreia/psicologia , Dietoterapia/métodos , Dietoterapia/normas , Europa (Continente) , Excipientes/efeitos adversos , Motilidade Gastrointestinal/efeitos dos fármacos , Motilidade Gastrointestinal/genética , Motilidade Gastrointestinal/imunologia , Motilidade Gastrointestinal/efeitos da radiação , Humanos , Lactose/efeitos adversos , Intolerância à Lactose/complicações , Intolerância à Lactose/diagnóstico , Intolerância à Lactose/etiologia , Anamnese , Oncologia/métodos , Estadiamento de Neoplasias , Neoplasias/sangue , Neoplasias/complicações , Cuidados Paliativos/métodos , Medicina de Precisão/métodos , Medicina de Precisão/normas , Autocuidado/métodos , Autocuidado/normas , Sociedades Médicas/normas , Procedimentos Cirúrgicos Operatórios/efeitos adversosRESUMO
Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not being met adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work.
Assuntos
Neoplasias/terapia , Cuidados Paliativos/métodos , Cuidados Paliativos/normas , Assistência Centrada no Paciente/métodos , Assistência Centrada no Paciente/normas , Humanos , Guias de Prática Clínica como Assunto , Qualidade de Vida , Assistência Terminal/métodos , Assistência Terminal/normasRESUMO
BACKGROUND: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. PATIENTS AND METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m2) cisplatin. Patients received ginger 160 mg/day (with standardized dose of bioactive compounds) or placebo in addition to the standard antiemetic prophylaxis for CINV, starting from the day after cisplatin administration. CINV was assessed through daily visual-analogue scale and Functional Living Index Emesis questionnaires. The main objective was protection from delayed nausea; secondary end points included intercycle nausea and nausea anticipatory symptoms. RESULTS: In total, 121 patients received ginger and 123 placebo. Lung (49%) and head and neck cancer (HNC; 35%) were the most represented tumors. No differences were reported in terms of safety profile or compliance. The incidence of delayed, intercycle and anticipatory nausea did not differ between the two arms in the first cycle and second cycle. A benefit of ginger over placebo in Functional Living Index Emesis nausea score differences (day 6-day 1) was identified for females (P = 0.048) and HNC patients (P = 0.038). CONCLUSIONS: In patients treated with high-dose cisplatin, the daily addition of ginger, even if safe, did not result in a protective effect on CINV. The favorable effect observed on nausea in subgroups at particular risk of nausea (females; HNC) deserves specific investigation.